Recent News

• 06.10.2026 - Nexalin Technology Reports Compelling Clinical Trial Results in Brazil to Support Product Launch. Trial Demonstrates 77.8% Anxiety Response Rate and Durable Benefits Across Depression, Insomnia and Quality of Life as Company Advances Brazilian Sales Plan.
• 06.04.2026 - Nexalin Technology Announces Issuance of U.S. Patent Covering Dynamic Frequency Stimulation for Anxiety, Depression and Insomnia
• 05.21.2026 - Nexalin Technology Secures Key Neurostimulation Legislative Provision & Commends U.S. House-Passed Report Language Expanding Non-Invasive Deep Brain Neurostimulation Research at the Department of Veterans Affairs for Traumatic Brain Injury
• 05.19.2026 - Nexalin Acquires AI-Integrated Digital Health Platform Behind HALO™ Clarity and Nexalin NeuroCare™ Ahead of Planned FDA Pivotal Trial
• 04.28.2026 - Nexalin Announces Peer-Reviewed Publication with Neuroimaging Data in Psychotherapy and Psychosomatics Highlighting Brain-Network Effects and Clinical Improvement in Chronic Insomnia
• 04.22.2026 - Nexalin Technology Advances Pivotal Clinical Trial of HALO™ Clarity Toward Q2 2026 Enrollment
• 04.15.2026 - Nexalin Advances FDA Alzheimer’s Strategy Following Landmark Leadership Meetings in the U.S. and China
• 04.14.2026 - Join Nexalin’s Exclusive Live Investor Webinar and Q&A Session on April 21
• 04.09.2026 - Nexalin Announces Peer-Reviewed Study Showing the Company’s DIFS™ Technology Reduced Self-Injury and Depression Symptoms in Female Adolescents
• 02.24.2026 - Nexalin Announces Pivotal HALO™ Clarity Trial to Support Planned De Novo FDA Submission Targeting Multi-Billion-Dollar Insomnia Market

Recent Filings

• 05.19.2026 - EX-99.1 EX-99.1
• 05.19.2026 - 8-K Current report
• 05.08.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 04.22.2026 - EX-99.1 EX-99.1
• 04.22.2026 - 8-K Current report
• 03.25.2026 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 02.25.2026 - 8-K Current report
• 02.25.2026 - EX-99.1 EX-99.1